US Capitol Capsule: Court rulings in gene patent, stem cell cases provide new hope for biopharma
This article was originally published in Scrip
Executive Summary
While the biopharmaceutical industry stands to capitalize on two landmark US court rulings issued last week – one affecting the future of government-funded human embryonic stem cell (hESC) research and the other the patenting of human genes – court watchers predict that neither case is settled.